Thursday, October 8, 2026 - Virtual Agenda

Learning Objectives:

• Review the epidemiology, pathophysiology, and risk factors for cancer-associated thrombosis (CAT).
• Apply current evidence and guideline recommendations to select the most appropriate anticoagulant for patients with CAT.
• Manage complex clinical scenarios, including thrombocytopenia, bleeding, recurrent VTE, and peri-procedural anticoagulation. Integrate contemporary ASCO, NCCN, and ISTH guideline recommendations into individualized clinical practice.

Peter Lamie, DO, Onco-hospitalist, University of Texas - MD Anderson Cancer Center

This activity is supported by an educational grant from AstraZeneca.

Learning Objectives:

• Apply current hypertension definitions and blood pressure targets to accurately diagnose and stage hypertension based on updated guideline recommendations.
• Incorporate cardiovascular risk assessment and comorbidities into individualized blood pressure decisions.
• Implement home and ambulatory blood pressure monitoring to improve diagnostic accuracy and guide therapy adjustments

Mark D. Baldwin, DO, MACOI, FASN (he/him/his), Professor & Chair, Division of Internal Medicine, Xavier University College of Osteopathic Medicine

Learning Objectives:

• Recognize appropriate timing for basal insulin initiation in patients with type 2 diabetes using guideline-aligned clinical indicators and real-world patient scenarios to reduce therapeutic inertia.
• Differentiate key pharmacologic characteristics of basal insulin therapies — PK/PD profiles, duration, variability, and hypoglycemia risk — and apply these to treatment selection
• Individualize basal insulin therapy by integrating patient-specific factors such as comorbidities, lifestyle, and hypoglycemia risk into evidence-based treatment decisions.

This activity is supported by an educational grant from Novo Nordisk.

Brian Lake, DO (he/him/his), Endocrinologist, Lake Endocrinology and Diabetes, PLLC

Learning Objectives:

• Apply evidence-based transfusion thresholds and component selection for red blood cells and platelets in common inpatient and perioperative clinical scenarios encountered by family physicians.
• Interpret basic coagulation patterns and recognize that an isolated prolongation of the PTT is rarely if ever an indication for plasma transfusion
• Identify clinical conditions that require urgent therapeutic apheresis and facilitate timely referral or consultation with transfusion medicine specialists.

Minh-Ha Tran, DO, Professor, University of California Irvine

Learning Objectives:

• Provide an overview and review of the complement system
• Describe the current FDA indicated complement inhibitors and their indications
• Explain the adverse effects and special considerations for patients on complement inhibitors

Nicholas Salupo, DO (he/him/his), Nephrologist, Dayton Kidney

Learning Objectives:

• Upon completion, participants will be able to list the expected timing related to when adverse effects occur with Immune Checkpoint Inhibitors.
• Upon completion, participants will be able to list most common and least common Endocrine Disorders associated with Immune Checkpoint Inhibitors.
• Upon completion, participants will be able to identify the mechanism of action of Immune Checkpoint Inhibitors.

John Sutton, DO, MACOI, FEAA, CCD, Endocrinologist, Carson Tahoe Endocrinology

Learning Objectives:

• Upon completion, participant will be able to list currently FDA-approved biomarkers for acute kidney injury and identify their appropriate clinical use in hospitalized patients.
• Upon completion, participant will be able to describe current clinical applications of AKI biomarkers based on KDIGO guidance and recent literature, including their role in risk stratification and early detection in high-risk populations.
• Upon completion, participant will be able to explain how transcriptomic biomarkers (mRNA and microRNA) may complement existing diagnostic approaches by enabling earlier detection, molecular subtyping, and precision management of acute kidney injury.

Danielle Janosevic, DO, MS, FASN (she/her/hers), Assistant Professor of Medicine, Indiana University

Learning Objectives:

• Identify key attributes of effective and inclusive leadership, including empathy, resilience, humility, integrity, and a sense of purpose.
• Differentiate between equality and equity and explain their relevance to inclusive leadership practices.
• Apply principles of inclusive leadership to promote collaboration, support others, and advance shared goals within healthcare teams and organizations.

Karen C. Caruth, MBA, CEO, ACOI

George M. Abraham, MD, MPH

Learning Objectives:

• Apply a contemporary, patient-centered approach to the evaluation and risk stratification of patients with atrial fibrillation.
• Select appropriate stroke-prevention therapy using current anticoagulation recommendations, bleeding-risk assessment, and shared decision-making.
• Compare rate-control and rhythm-control strategies, including antiarrhythmic medications, cardioversion, and catheter ablation, to individualize treatment and improve clinical outcomes.

Chad A. Link, DO, FACC, FACOI, Cardiologist, University of Michigan Health- Sparrow

Learning Objectives:

• Upon completion, participant will be able to define Dysadiposity and appreciate its pathophysiologic dynamics.
• Upon completion, participant will be able to appreciate the physiology of Appetite Regulation.
• Upon completion, participant will be able to appreciate the collective scope of both integrative and pharmacologic treatment strategies.

Eric S. Langer, DO, MACOI, Physician, William Beaumont/Corwell Hospital - Troy, Michigan

Learning Objectives:

• Upon completion, participant will be more aware of the harms that can, and do, occur as a result of tests and/or procedures that could have been avoided
• Upon completion, participant will be more aware of the wastefulness of extensive patient testing when ordered inappropriately
• Upon completion, participant will be more aware of the problems created when tests and/or procedures are applied or prescribed indiscriminately

Gerald W. Blackburn, DO, MACOI, Clinical Professor of Medicine, Michigan State University, College of Osteopathic Medicine

Albert M. Brady, MD, FACP, FACOI (he/him/his), Professor, Internal Medicine, Pacific Northwest University of the Health Sciences, COM

John A. Frith, DO, FAAAAI FACOI, Allergy/Immunology Physician, Michigan State College of Osteopathic Medicine

Nicholas Salupo, DO (he/him/his), Nephrologist, Dayton Kidney

Learning Objectives:

• Upon completion, participants will be able to detail the difference between Adrenal fatgue and Adrenal Insufficiency.
• Upon completion, participants will be able to describe Wilson Temperature syndrome and the American Thyroid Association position on this diagnosis.
• Upon completion, participants will be able to identify the factors needed to determine the need for prescribing testosterone.

John Sutton, DO, MACOI, FEAA, CCD, Endocrinologist, Carson Tahoe Endocrinology

Learning Objectives:

• Apply the 2026 ACC/AHA/Multisociety dyslipidemia framework to assess cardiovascular risk and select appropriate LDL-C and non-HDL-C treatment goals.
• Use PREVENT risk estimates, coronary artery calcium scoring, risk-enhancing factors, ApoB, and lipoprotein(a) to personalize lipid-management decisions.
• Select and sequence statin and nonstatin therapies based on ASCVD risk, degree of LDL-C lowering needed, triglyceride burden, medication tolerance, adherence, and access.

Chad A. Link, DO, FACC, FACOI, Cardiologist, University of Michigan Health- Sparrow

Learning Objectives:

• Define mild autonomous cortisol secretion (MACS) and distinguish it from overt Cushing's syndrome
• Apply current diagnostic criteria, including the 1-mg overnight dexamethasone suppression test (DST) and its interpretation
• Interpret key findings from the CATALYST clinical trial and their implications for internal medicine practice

Brian Lake, DO (he/him/his), Endocrinologist, Lake Endocrinology and Diabetes, PLLC

Activity has been supported by an educational grant from Bayer Healthcare Pharmaceuticals, Inc. and Astellas Pharma Global Development, Inc.

Learning Objectives:

• upon completion of this exercise the provider should feel comfortable discussing HRT with their patients.
• upon completion, participants will be able to offer non hormonal treatment of vasomotor symptoms.
• upon completion, participants should know what labs to order on their perimenopausal and menopausal women.

Mia Lynne Van Eken, DO (she/her/hers), Physician, East Valkey Women for Women Director of GYN Creighton residency East Valley

Learning Objectives:

• Participants will gain a better understanding of how albuminuria guides CKD treatments
• Participants will get an overview of the practical considerations undertaken when prescribing CKD-focused guideline directed medical therapy
• Participants will learn about the opportunities we have to improve collaboration between primary care and nephrology

Brian Brady, MD (he/him/his), Clinical Associate Professor of Medicine, Stanford University School of Medicine

Learning Objectives:

• Upon completion, participants will be able to understand the use of likelihood ratios in determining the accuracy of diagnostic tests.
• Upon completion, participant will be able to identify some of the best tests to use in everyday practice which will help improve their diagnostic accuracy.
• Upon completion, participant will be able to recognize the importance of their daily bedside physical examination in clinical practice.

Richard A. Shellenberger, DO, MACP (he/him/his), Associate Program Director, Trinity Health Ann Arbor Hospital, Michigan

Learning Objectives:

• Recognize the prevalence, burden, and clinical impact of migraine in adult internal medicine populations.
• Apply evidence-based diagnostic criteria to accurately diagnose migraine and distinguish it from other headache disorders.
• Implement guideline-supported acute and preventive migraine treatment strategies within internal medicine practice.

Steven T. Dinsmore, DO, FACOI (he/him/his), Retired, FDA